EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma.
Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK, Friedrich MJ, Michel CS, Hajiyianni M, Breitkreutz I, Costello P, Nadeem O, Weinhold N, Goldschmidt H, Schmitt A, Luft T, Schmitt M, Müller-Tidow C, Topp M, Einsele H, Dreger P, Munshi NC, Sperling AS, Rasche L, Sauer S, Raab MS.
Frenking JH, et al. Among authors: luft t.
J Immunother Cancer. 2024 Oct 7;12(10):e009220. doi: 10.1136/jitc-2024-009220.
J Immunother Cancer. 2024.
PMID: 39379098
Free PMC article.